Genzyme 2Q 2Q Revenues: $1.2 billion (+5%) 2Q Earnings: $192.2 million (earnings were $69.6 million in 2Q08) Comments: Myozyme revenue was $79.3 million, up from $67.4 million in 1Q09, reflecting the E.U. approval of production at the 4000 L scale. Cerezyme revenue was down 7% to $298.1 million, impacted by the temporary Allston shutdown and unfavorable currency exchange rates. Sales of Fabrazyme were $134.3 million (+6%). Sales of Thyrogen were $42.9 million (+9%). Hematologic oncology...